Skip Navigation
 
 
 
 
 
 
>
 
 
>
 
 
>
 
 
 
  Search the Site

 
 

Center for Global Health Faculty

Joel Gallant, MD, University of California, San Francisco, 1985; MPH, Johns Hopkins University School of Hygiene and Public Health, 2000

Associate Director, Johns Hopkins AIDS Service

Contact Information

Division of Infectious Diseases
1830 E. Monument St. Room 443
410-955-7473
410-614-8488

SciVal Experts Research Profile

Education

MD, University of California, San Francisco, 1985; MPH, Johns Hopkins University School of Hygiene and Public Health, 2000

Overview

My interest is primarily in clinical trials of new antiretroviral agents (phase 2-4), both in the United States and in developing countries. I also conduct research on the natural history of HIV infection and its complications. I am an investigator in the HIV Prevention Trials Network (HPTN), the Multicenter AIDS Cohort (MACS), and the AIDS Clinical Trials Group (ACTG). Within the HPTN and ACTG I have been involved in international clinical trials, especially in Chiang Mai, Thailand.

Honors and Awards

John C. Hume Masters in Public Health Award, 1990 Delta Omega Public Health Honor Society, Alpha Chapter, 1990 Emerging Leader in Clinical Education award, HIV Medicine Association, Infectious Disease Society of America

HIV, AIDS, antiretroviral therapy, resistance, clinical trials, drug development

  • Gallant JE, Moore RD. Renal function with use of a tenofovir-containing initial antiretroviral regimen. AIDS 2009 [in press]. Apuzzo LG, Vaida F, Gallant JE, et al. Tolerability and efficacy of PI- versus NNRTI-based regimens in subjects receiving HAART during acute or early HIV infection. J Acquir Immune Defic Syndr 2009;50:267-75. Grant P, Taylor J, Cain P, et al. Maintaining reduced viral fitness and CD4 response in HIV-infected patients with viremia on a boosted protease inhibitor. Clin Infect Dis 2009;48:680-2. Wilson L, Gallant JE. Treatment experienced HIV patients: New drugs and drug combinations. Clin Infect Dis 2009;48:214-21. Gallant JE, Winston, JA, DeJesus E, Pozniak et al. The three-year renal safety of a tenofovir DF- vs. a thymidine analog-containing regimen in antiretroviral-naïve patients. AIDS 2008; 22:2155-2163. Nachega JB, Hislop M, Dowdy DW, et al. Efavirenz versus nevirapine-based initial treatment of HIV infection: clinical and virological outcomes in southern African adults. AIDS 2008;22:2117-25. Solomon SS, Hawcroft CS, Narasimhan P, et al. Comorbidities among HIV-infected injection drug users in Chennai, India. Indian J Med Res 2008:127:458-63. Arribas JR, Pozniak, AL, Gallant JE, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis. J Acquir Immune Defic Syndr 2008;47:74-78. Han Y, Lai J, Barditch-Crovo P, et al. The role of protective HCP5 and HLA-C associated polymorphisms in the control of HIV-1 replication in a subset of elite suppressors. AIDS 2008;22:521-4. Riddell J 4th, Kaul DR, Karakousis PC, et al. Mycobacterium avium complex immune reconstitution inflammatory syndrome: Long term outcomes. J Transl Med 2007;5:50. Haubrich R, Berger D, Chiliade P, et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced patients. AIDS 2007;21:F11-18. Siliciano JD, Lai J, Callender M, et al. Stability of the latent reservoir for HIV-1 in patients receiving valproic acid. J Infect Dis 2007;195:833-6. Pozniak AL, Gallant JE, DeJesus E, et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naïve patients: virologic, immunologic, and morphologic changes: a 96-week analysis. J Acquir Immune Defic Syndr 2006;43:535-40. Li X, Chu H, Gallant JE, Hoover DR, et al. Bimodal virologic response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health 2006;60:811-8. Atta M, Gallant JE, Rahman H, Nagajothi N, Racusen LC, Scheel PJ, Fine DM. Antiretroviral therapy in the treatment of HIV-associated nephropathy. Nephrol Dial Transplant 2006 [in press]. Li X, Chu H, Gallant JE, Hoover DR, Mack WJ, Chmiel JS, Muñoz A. Bimodal virologic response to antiretroviral therapy for HIV infection: an application using a mixture model with left censoring. J Epidemiol Community Health 2006 [in press]. Pham PA, Gallant JE. Tenofovir disoproxil fumarate for the treatment of HIV infection. Expert Opin Drug Metab Toxicol 2006;2:459-69. Estrella M, Fine DM, Gallant JE, Rahman MH, Nagajothi N, Racusen LC, Scheel PJ, Atta MG. HIV type 1 RNA level as a clinical indicator of renal pathology in HIV-infected patients. Clin Infect Dis 2006;43:377-80. Bailey JR, Sedaghat AR, Kieffer T, Brennan T, Lee PK, Wind-Rotolo M, Haggerty CM, Kamireddi AR, Liu Y, Lee J, Persaud D, Gallant JE, Cofrancesco J Jr, Quinn TC, Wilke CO, Ray SC, Siliciano JD, Nettles RE, Siliciano RF. Residual human immunodeficiency virus type 1 viremia in some patients on antiretroviral therapy is dominated by a small number of invariant clones rarely found in circulating CD4+ T cells. J Virol. 2006;80:6441-57. Doherty MC, Gallant JE. Current issues in initiation of antiretroviral therapy. Infect Med 2006;22:599-615.

      
About the Center l News Center l Event Calendar l Resources l Facebook l Contact Us
Student Travel Grants l Faculty Grants l Scholars l Events & Seminars l Collaborative Projects l Project Database

© 2011-2018 Johns Hopkins Center for Global Health